Adam Friedman, MD, FAAD defines non-medical therapeutic switching and discusses common tactics payors use to pressure practitioners and patients to switch.
Back
Expert Perspectives on the Clinical Impact of Non-Medical Therapeutic Switching
Adam Friedman, MD, FAAD provides insight into how and why insurance companies implement non-medical therapeutic switching and what healthcare providers can do to mitigate its impact on patient care.
Expert Perspectives on the Clinical Impact of Non-Medical Therapeutic Switching
Episodes
All
All
An expert in dermatology discusses the potential impact of non-medical switching to biosimilars and generic formulations on safety and efficacy profiles.
Adam Friedman, MD, FAAD provides insight into how non-medical therapeutic switching affects clinical, economic, and psychological outcomes for patients.
A key opinion leader emphasizes the importance of discouraging non-medical switching by communicating with patients and partnering with industry researchers.
Adam Friedman, MD, FAAD discusses how payors accelerated non-medical switching during COVID-19 and how healthcare providers can respond to new challenges.
Advertisement
Advertisement
Trending on HCPLive
1
ASH Issues New Ferritin Thresholds for Iron Deficiency Diagnosis
2
Vicadrostat EASi-KIDNEY Trial Discontinued for Lack of Benefit in CKD
3
Antifungal Therapy Eased IBD Activity, With Iliyan D. Iliev, PhD
4
Interpreting CMR GUIDE’s Mixed Results for ICD Implantation, With Joseph Selvanayagam, MBBS
5